- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03868046
Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) (AUTENTIC)
Prediction of Immune-related Adverse Events Induced by Anti-CTLA4 and Anti-PD1/PDL1 Drugs by Means of a Battery of Autoantibodies. A Multicenter Prospective Observational Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction: Treatment with ICIs is leading to a remarkable improvement in the prognosis of several types of cancer. However, the expansion of these drugs in the field of oncology is also causing the emergence of a large diversity of irAEs, whose optimal prevention and management are still to be clarified. Nowadays, there is a growing need for reliable and validated biomarkers to predict the occurrence of irAEs in patients treated with ICIs.
Purpose: To assess the effectiveness of a battery of autoantibodies available in a laboratory of autoimmunity to predict the occurrence of irAEs in patients with cancer who will be treated with ICIs per standard protocol.
Methods: A multicenter prospective observational cohort study was designed to include a total of 221 patients diagnosed with cancer amenable to treatment with ICIs. During a period of 48 weeks, patients will be controlled in the oncology outpatient clinics of five university hospitals with accredited experience in the management of immunotherapy. Immune-related adverse events will be defined and categorized according to CTCAE v. 5.0. Considering a proportion of irAEs and losses to follow-up of 25% and 5% respectively, a sample size of 221 patients was calculated to estimate an expected sensitivity of the autoantibody battery of 0.90 with a 95% confidence interval not lower than 0.75. All the participants will undergo ordinary blood tests at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE. Both ordinary and extraordinary samples will be frozen and stored in the biobank of each participating hospital in the form of serum and buffy coat. Once the whole cohort reaches the 24th week (intermediate analysis) and the 48th week (definitive analysis), all the samples will be centralized in the same autoimmunity laboratory for the determination of the autoantibody battery. A predictive model of irAEs will be constructed with the autoantibodies together with other potential risk factors of immune-mediated toxicity.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Álava
-
Vitoria, Álava, Spain, 01009
- Recruiting
- Hospital Universitario Araba
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Initiation of treatment with a single ICI or a combination of ICIs.
- Acceptation of an informed consent.
Exclusion Criteria:
- Life expectancy lower than 3 months from the initiation of treatment with ICIs.
- Proven hypersensitivity or previous allergic anaphylactic reaction induced by a specific ICI.
- Active autoimmune disease with severe involvement.
- Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3.
- Ongoing immunosuppressive therapy: prednisone at doses >10 mg/day or equivalent (>1.5 mg/day of dexamethasone), and/or any dose of azathioprine, methotrexate, mycophenolate, cyclophosphamide, leflunomide, rituximab, anti-tumor necrosis factor drugs (infliximab, etanercept, adalimumab, golimumab), belimumab and abatacept.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients treated with ICIs.
All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
|
Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of irAEs.
Time Frame: At 48 weeks from the initiation of ICIs.
|
An irAE was defined as any symptom, sign, syndrome or disease attributable to an immune activation mechanism during an ongoing treatment with an ICI or a combination of ICIs, provided that an infectious cause and/or tumor progression have been ruled out.
|
At 48 weeks from the initiation of ICIs.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
irAE-free survival.
Time Frame: At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Time in months from the initiation of therapy with ICIs until the occurrence of an irAE or until the date of the last follow-up.
|
At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Progression-free survival.
Time Frame: At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Time in months from the initiation of therapy with ICIs until the date of proven tumor progression or until the date of the last follow-up.
|
At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Overall survival.
Time Frame: At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Time in months from the initiation of therapy with ICIs until the date of patient's death or until the date of the last follow-up.
|
At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Incidence of development of autoantibodies.
Time Frame: At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Positive conversion of the autoantibody battery after the initiation of therapy with ICIs.
|
At 24 weeks and at 48 weeks from the initiation of ICIs.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2018106 (EPA-SP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Treatment with immune checkpoint inhibitors.
-
Institut BergoniéInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedCancer Treated With Immune-checkpoint InhibitorsFrance
-
The Affiliated Hospital of Qingdao UniversityCompletedNSCLC | Angiogenesis | ImmunotherapyChina
-
Yong Zhang,MDRecruitingUterine Cervical NeoplasmsChina
-
Grit BiotechnologyNot yet recruiting
-
Anhui Provincial HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
ETOP IBCSG Partners FoundationUSZ FoundationRecruitingMelanoma | Non-Small Cell Lung CancerSwitzerland, Netherlands, Italy, United Kingdom
-
Xuzhou Medical UniversityRecruitingLung Squamous Cell CarcinomaChina
-
Institut Claudius RegaudRecruiting
-
Institut Paoli-CalmettesSociété Francophone d'Onco-GériatrieUnknownAdvanced or Metastatic NSCLC | Advanced or Metastatic MelanomaFrance
-
First Affiliated Hospital Xi'an Jiaotong UniversityFujian Cancer Hospital; Henan Cancer Hospital; The First Affiliated Hospital... and other collaboratorsNot yet recruiting